Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese
× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("New Discussion" button below). Please include the country of origin.

Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM PHYSICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

Suboptimal Response with Poor Alternatives

  • Jeff Lipton
  • Jeff Lipton's Avatar Topic Author
10 years 7 months ago #791 by Jeff Lipton
Suboptimal Response with Poor Alternatives was created by Jeff Lipton
. I was referred a male patient. He is 55 now, diagnosed in Sep 2011 with low risk CML ( Sokal and Hasford ). Karyotype showed 9:22 in all and in 2/20 cells an additional trisomy 8 . Started on imatinib and achieved HR and CCR was achieved after 11 months but he never achieved MMR. Despite 6 months of dasatinib and then 4 months of nilotinib still has not achieved MMR but still in hematological remission. The QPCR is stable but transcripts are greater than 1 %. Mutation analysis is negative and he is compliant. Repeat marrow this month is normal with a normal karyotype. Peripheral blood FISH remains negative. His 2 sibs are not HLA matches. Should I look for an unrelated donor ? Is there a role for Bosutinib or Ponatinib ? Patient is obese and a smoker. My general feeling is that I probably would not have switched him from imatinib to begin with, but definitely do not see a role for another switch, either because of expected efficacy and potential for toxicity. I would see if there is an unrelated donor out there in case he loses response, but otherwise would hold tight and monitor carefully. Any other thoughts.
Quick Reply

Reply to Jeff Lipton

Your e-mail address will only be available to administators.
Go to editor..
Note: BBcode and smileys are still usable.
  • Michele Baccarani
  • Michele Baccarani's Avatar Topic Author
10 years 7 months ago #799 by Michele Baccarani
Replied by Michele Baccarani on topic Re: Suboptimal Response with Poor Alternatives
I agree almost completely with your proposal and I would continue the current TKI, monitoring every 3 months for molecular response and every 12 months for cytogenetic response (marrow cell metaphases, because there was a trisomy 8, although trisomy 8 can be seen also by FISH). It is unusual that a patient with stable CCyR does not achieve an MMR, with imatinib, and particularly with second generation TKIs. I understand that he’s compliant, but……..nobody knows! And there may be problems of drug absorption and metabolism. I suggest to contact your Novartis contact to plan a measurement of blood drug concentration. I suggest also to take care of the “cardiovascular” conditions, using the Edinburgh questionnaire for claudicatio, with a periodic evaluation of the ABI, and with an ultrasound evaluation of epiaortic vessels, and of some metabolic indicators like blood glucose, cholesterol and HDL. Best wishes, Michele
Quick Reply

Reply to Michele Baccarani

Your e-mail address will only be available to administators.
Go to editor..
Note: BBcode and smileys are still usable.
Moderators: Nicola, arlene